Cart summary

You have no items in your shopping cart.

Ponesimod

SKU: orb1223849

Description

A potent, selective, orally active S1P1 receptor agonist with EC50 of 9.1 nM; shows weak activity on S1P3 (EC50=123 nM); activates S1P1-mediated signal transduction with high potency (EC50 of 5.7 nM); causes maximal reduction of circulating lymphocytes at a dose of 3 mg/kg.Multiple Sclerosis Phase 3 Clinical(In Vitro):Ponesimod activates human S1P1-5 receptors with EC50s of 5.7, >10000, 105, 1108 and 59.1 nM respectively in GTPγS binding assay.Ponesimod activates S1P1 receptors with EC50s of 5.7, 1.9, and 1.4 nM for human, rat, and mouse S1P receptors respectively.(In Vivo):Ponesimod (30 and 175 mg/kg; once daily p.o. for 8 d) prevents delayed-type hypersensitivity in mice.Ponesimod (30 mg/kg by gavage 3 h before and 6 h after adjuvant injection followed by 100 mg/kg/day by administration as food admix for 18 days) prevents adjuvant-induced arthritis in rats.Ponesimod (0.3-100 mg/kg; a single oral gavage) causes a dose-dependent reduction in lymphocyte count, with a plateau effect being reached at 3 mg/kg in rats.Ponesimod (100 mg/kg; once daily oral gavage for 7 d) results in a lymphocyte count reduction to 1900 lymphocytes/μL, and this effect is maintained over the entire 7 days studies. Lymphocyte count returned to baseline levels within 48 h after discontinuation of dosing.

Images & Validation

Key Properties

CAS Number854107-55-4
MW460.9736
Purity>98% (HPLC)
FormulaC23H25ClN2O4S
SMILESO=C1N(C2=CC=CC=C2C)/C(S/C1=C\C3=CC=C(OC[C@H](O)CO)C(Cl)=C3)=N/CCC
TargetLysophospholipid Receptor
Solubility10 mM in DMSO

Bioactivity

In Vivo
Animal model: Female BALB/c mice (15-25 g) sensitized with DNFB. Dosage: 30 and 175 mg/kg. Administration: Gavage (30 mg/kg) 19 and 3 h before sensitization, followed by administration as food admix (175 mg/kg/day) for 8 days. Result: Caused a 60 to 90% reduction of delayed-type hypersensitivity (DTH) parameters of the skin, such as edema, protein extravasation, and neutrophil myeloperoxidase (MPO) activity. Reduced skin levels of proinflammatory cytokines, such as IL-1β, IL-6, IFNγ, TNFα, and several chemokines to different degrees ranging from-27 to-100%.

Storage & Handling

StorageStorage temperature: -20°C. Stability: ≥ 2 years
Expiration Date12 months from date of receipt.
DisclaimerFor research use only

Alternative Names

ACT-128800

Similar Products

  • Ponesimod [orb1304376]

    99.96%

    854107-55-4

    460.97

    C23H25ClN2O4S

    2 mg, 5 mg, 10 mg, 100 mg, 1 ml x 10 mM (in DMSO), 50 mg, 1 mg, 25 mg, 500 mg
  • Ponesimod-d7 [orb3138660]

    10 mg, 50 mg
Quality Guarantee

Quality Guarantee

Explore bioreagents carefree to elevate your research. All our products are rigorously tested for performance. If a product does not perform as described on its datasheet, our scientific support team will provide expert troubleshooting, a prompt replacement, or a refund. For full details, please see our Terms & Conditions and Buying Guide. Contact us at [email protected].

Documents Download

Datasheet
Product Information
Download

Request a Document

Protocol Information

Ponesimod (orb1223849)

  • Star
  • Star
  • Star
  • Star
  • Star
  • 0.0
Based on 0 reviews

Participating in our Biorbyt product reviews program enables you to support fellow scientists by sharing your firsthand experience with our products.

Login to Submit a Review

No reviews yet

Step 1: Enter information below

(Recommended: An additional animal making an allowance for loss during the experiment)

Step 2: Enter the in vivo formulation

(This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO +
%+
% Tween 80 +
%

Available Sizes

Select a size below

2 mg
$ 100.00
5 mg
$ 140.00
10 mg
$ 200.00
25 mg
$ 350.00
50 mg
$ 570.00
100 mg
$ 830.00
500 mg
$ 1,750.00